var data={"title":"Lansoprazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lansoprazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6434?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lansoprazole-drug-information\" class=\"drug drug_general\">see &quot;Lansoprazole: Drug information&quot;</a> and <a href=\"topic.htm?path=lansoprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lansoprazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836891\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186757\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Lansoprazole;</li>\n      <li>GoodSense Lansoprazole [OTC];</li>\n      <li>Heartburn Relief 24 Hour [OTC] [DSC];</li>\n      <li>Heartburn Treatment 24 Hour [OTC];</li>\n      <li>Prevacid;</li>\n      <li>Prevacid 24HR [OTC];</li>\n      <li>Prevacid SoluTab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186758\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prevacid;</li>\n      <li>Prevacid FasTab</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059660\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastric Acid Secretion Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Proton Pump Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12860309\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>GERD:</b> Oral: Limited data available; dose not established; ideal dose-response not established: 0.5 to 1.5 mg/kg/day as a single dose or divided twice daily has been shown to be well tolerated and improve gastric pH; 0.5 to 1 mg/kg administered once daily was evaluated in 24 neonates (mean PNA: 3.7 &plusmn; 4 weeks, mean weight: 3.015 &plusmn; 0.893 kg); this regimen resulted in increased gastric pH and was associated with a decreased frequency of GERD symptoms (Springer, 2008).  In another  study, 10 VLBW premature neonates (mean PNA: 3.6 &plusmn; 1.49 weeks, mean weight: 1.13 &plusmn; 0.03 kg) received 1.5 mg/kg/day divided twice daily; although gastric pH increased it was not adequate to protect from esophagitis (Tham, 2012).  A pharmacokinetic study showed patients &lt;10 weeks of age had substantially decreased clearance and suggests a lower dose should be used (~0.2 mg/kg/day) (Zhang, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059653\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lansoprazole-drug-information\" class=\"drug drug_general\">see &quot;Lansoprazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>GERD, symptomatic: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Weight-based dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants: 1 to 2 mg/kg/day (Orenstein, 2009; Springer, 2008; Zhang, 2008). <b>Note:</b> A pharmacokinetic study showed patients &lt;10 weeks of age had substantially decreased clearance and suggests a lower dose should be used (~0.2 mg/kg/day) (Zhang, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children: 0.7 to 3 mg/kg/day (AAP [Lightdale], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Infants &ge;3 months: 7.5 mg twice daily <b>or</b> 15 mg once daily was shown to provide better symptom relief compared to dietary management in 68 patients (Khoshoo, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 1 to 11 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&le;30 kg: 15 mg once daily for up to 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;30 kg: 30 mg once daily for up to 12 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &ge;12 years and Adolescents: Oral: 15 mg once daily for up to 8 weeks\t</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Erosive esophagitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1-11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&le;30 kg: 15 mg once daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;30 kg: 30 mg once daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;12 years and Adolescents: Oral: 30 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Duodenal ulcer:</b> Oral: 15 mg once daily for 4 weeks; maintenance therapy: 15 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Erosive esophagitis:</b> Oral: 30 mg once daily for up to 8 weeks; additional 8 weeks may be tried in those patients who failed to respond or for a recurrence of esophagitis; maintenance: 15 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gastric ulcer:</b> Oral: 30 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>GERD, symptomatic:</b> Oral: 15 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Hypersecretory conditions:</b> Oral: Initial: 60 mg once daily; adjust dosage based upon patient response and to reduce acid secretion to &lt;10 mEq/hour (5 mEq/hour in patients with prior gastric surgery); doses of 90 mg twice daily have been used; administer doses &gt;120 mg/day in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Helicobacter  pylori</i> eradication:</b> Oral: 30 mg twice daily for 2  weeks (in combination with amoxicillin and clarithromycin). Alternatively, in patients allergic to or intolerant of clarithromycin or in whom resistance to clarithromycin is known or suspected, lansoprazole 30 mg every 8 hours may be given for 2 weeks (in combination with amoxicillin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>NSAID-associated gastric ulcer:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Healing: 30 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Prevention: 15 mg once daily for up to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Heartburn:</b> OTC labeling: Oral: 15 mg once daily for 14 days; may repeat 14 days of therapy every 4 months. Do not take for &gt;14 days or more often than every 4 months, unless instructed by healthcare provider.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults: No dosage adjustments are recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: Bioavailability increased in hepatic impairment; consider dose reduction for severe impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186730\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Lansoprazole: 15 mg [gluten free; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Relief 24 Hour: 15 mg [DSC] [sodium free; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heartburn Treatment 24 Hour: 15 mg [sodium free; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevacid: 15 mg, 30 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevacid 24HR: 15 mg [sodium free; contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Lansoprazole: 3 mg/mL (90 mL, 150 mL, 300 mL) [contains benzyl alcohol, fd&amp;c red #40, saccharin sodium; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prevacid SoluTab: 15 mg, 30 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186715\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040050\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=lansoprazole-drug-information\" class=\"drug drug_general\">see &quot;Lansoprazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">First-Lansoprazole suspension is a compounding kit. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15241705\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevacid capsules, orally disintegrating tablets: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020406s083,021428s031lbl.pdf#page=37&amp;token=xroqo9lC/w4I8Ivp6IrhfXLbKGJYTSTJM1O7EbYew5A1Vf+2bRtU8GMgly5VDVGdKwogEc6sx49ZSrwOeLsSAKpF1lZT74JS23b4MyamU+EkMu+cLY1HRzL8F9OoKEYm&amp;TOPIC_ID=12543\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020406s083,021428s031lbl.pdf#page=37</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059664\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Oral: Administer before eating; best if taken 30 minutes before a meal (Lightdale 2013); intact granules should not be chewed or crushed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules: Swallow whole; do not chew or crush. For patients with difficulty swallowing the capsule, capsules may be opened and the intact granules sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, yogurt, or strained pears; the mixture should be swallowed immediately. Capsules may also be opened and emptied into ~60 mL of apple juice, orange juice, or tomato juice; mix and swallow immediately. Rinse the glass with additional juice and swallow to assure complete delivery of the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For nasogastric tube &ge;16 French: Capsule can be opened, the granules mixed (not crushed) with 40 mL of apple juice and then injected through the NG tube into the stomach, then flush tube with additional apple juice. Do not mix with other liquids based on manufacturer labeling; additional information may be available for NG administration; contact manufacturer to obtain current recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, orally-disintegrating: Should not be swallowed whole, broken, cut, or chewed. Place the tablet on the tongue and allow to disintegrate with or without water until the particles can be swallowed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Administration via an oral syringe: Place the 15 mg tablet in an oral syringe and draw up ~4 mL water, or place the 30 mg tablet in an oral syringe and draw up ~10 mL water. Shake gently. After tablet has dispersed, administer within 15 minutes. Refill the syringe with water (2 mL for the 15 mg tablet; 5 mL for the 30 mg tablet), shake gently, then administer any remaining contents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For nasogastric tube &ge;8 French: Place a 15 mg tablet in a syringe and draw up ~4 mL water, or place the 30 mg tablet in a syringe and draw up ~10 mL water. Shake gently. After tablet has dispersed, administer within 15 minutes. Refill the syringe with ~5 mL water, shake gently, and then flush the nasogastric tube.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186752\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules, orally disintegrating tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for suspension (First Lansoprazole compounding kit): Prior to compounding, store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Once compounded, the product is stable for 30 days at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from freezing. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059663\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Short-term treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;1 year and adults); short-term treatment (up to 8 weeks) for healing and symptomatic relief of all grades of erosive esophagitis (FDA approved in ages &ge;1 year and adults); maintenance of healed erosive esophagitis (FDA approved in adults); short-term treatment (up to 8 weeks) of active benign gastric ulcer (FDA approved in adults); short-term treatment (&le;4 weeks) for healing and symptomatic relief of active duodenal ulcer (FDA approved in adults); maintenance treatment of healed duodenal ulcers (FDA approved in adults); treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (FDA approved in adults); adjuvant therapy in the treatment of duodenal ulcers associated with <i>Helicobacter pylori</i> (FDA approved in adults); prevention (for patients at high risk) and treatment of NSAID-associated gastric ulcers (FDA approved in adults); relief of frequent heartburn (&ge;2 days/week) (OTC product: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186815\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lansoprazole may be confused with aripiprazole, dexlansoprazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prevacid may be confused with Pravachol, Prevpac, PriLOSEC, Prinivil</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria  as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided unless given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett&rsquo;s esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H2 blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186813\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Abnormal albumin-globulin ratio, albuminuria, decreased serum cholesterol, hyperlipidemia, increased gamma-glutamyl transferase, increased gastrin, increased lactate dehydrogenase, increased serum glucocorticoids, increased serum potassium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, occult blood in stools</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Crystalluria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal erythrocytes, blood platelet disorder (abnormal platelets), leukocyte disorder, leukocytosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Increased serum globulins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute interstitial nephritis, increased blood urea nitrogen, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal distention, abnormal dreams, abnormal stools, abnormality in thinking, acne vulgaris, ageusia, agitation, agranulocytosis, alopecia, altered sense of smell, amblyopia, amnesia, anaphylactoid reaction, anaphylaxis, anemia, angina pectoris, anorexia, anxiety, apathy, aphthous stomatitis, aplastic anemia, arthralgia, arthritis, arthropathy, asthma, back pain, bezoar formation, blepharitis, blepharoptosis, blurred vision, bone disease, bone fracture, bradycardia, breast hypertrophy, breast tenderness, bronchitis, candidiasis, carcinoma, cardiac arrhythmia, cataract, cerebral infarction, cerebrovascular accident, change in platelet count (decreased/increased), chest pain, chills, cholelithiasis, circulatory shock, <i>Clostridium difficile</i> associated diarrhea, colitis, confusion, conjunctivitis, contact dermatitis, cough, cutaneous lupus erythematosus, deafness, decreased libido, dehydration, dementia, depersonalization, depression, dermatological disease, diabetes mellitus, diaphoresis, difficulty in micturition, diplopia, dizziness, drowsiness, dry eye syndrome, dysgeusia, dysmenorrhea, dyspepsia, dysphagia, dyspnea, dysuria, ear disease, edema, electrolyte disturbance (decreased/increased), emotional lability, enteritis, eosinophilia, epistaxis, eructation, erythema multiforme, esophageal achalasia, esophageal stenosis, esophageal ulcer, esophagitis, eye pain, fecal discoloration, fever, fixed drug eruption, flatulence, flu-like symptoms, gastritis, gastroenteritis, gastrointestinal hemorrhage, GI moniliasis, gingival hemorrhage, glaucoma, glossitis, glycosuria, goiter, gout, gynecomastia, hair disease, halitosis, hallucination, hematemesis, hemiplegia, hemolysis, hemolytic anemia, hemoptysis, hepatotoxicity, hiccups, hostility, hyperkinesia, hypermenorrhea, hypersensitivity reaction, hypertension, hypertonia, hypoesthesia, hypoglycemia, hypomagnesemia, hypotension, hypothyroidism, impotence, increased appetite, increased libido, increased thirst, infection, insomnia, interstitial nephritis, leg cramps, leukopenia, leukorrhea, lymphadenopathy, maculopapular rash, malaise, malignant neoplasm of larynx, mastalgia, melena, menstrual disease (includes abnormal menses), migraine, musculoskeletal pain, myalgia, myasthenia, myocardial infarction, myositis, nail disease, neck pain, neck stiffness, nephrolithiasis, nervousness, neutropenia, oral mucosa ulcer, otitis media, pain, palpitations, pancreatitis, pancytopenia, paresthesia, pelvic pain, penile disease, peripheral edema, pharyngitis, photophobia, pleural disease, pneumonia, polyp (gastric nodules and fundic gland polyp), polyuria, pruritus, psychoneurosis, pulmonary fibrosis, rectal disease, rectal hemorrhage, renal disease (chronic; Lazarus 2016), renal pain, respiratory tract disease, retinal degeneration, retinopathy, rhinitis, seizure, sialorrhea, sinusitis, skin carcinoma, skin rash, sleep disorder, speech disturbance, Stevens-Johnson syndrome, stomatitis, stridor, syncope, synovitis, systemic lupus erythematosus, tachycardia, tenesmus, testicular disease, thrombocytopenia, thrombotic thrombocytopenic purpura, tinnitus, tremor, tongue disease, toxic epidermal necrolysis, ulcerative colitis, upper respiratory tract inflammation, upper respiratory tract infection, urethral pain, urinary frequency, urinary retention, urinary tract infection, urinary urgency, urticaria, vaginitis, vasodilatation, vertigo, visual disturbance, visual field defect, vitamin deficiency, vomiting, weakness, weight gain, weight loss, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186738\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, angioedema, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria) to lansoprazole or any component of the formulation; concomitant use with products that contain rilpivirine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186719\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to elderly patients. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to a specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of lansoprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of lansoprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years of age); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Patients with severe liver dysfunction may require dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). Although lansoprazole exhibits the most potent CYP2C19 inhibition <i>in vitro</i> (Li 2004; Ogilvie 2011), an <i>in vivo</i> study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel by lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger 2012). The manufacturer of lansoprazole states that no dosage adjustment is necessary for clopidogrel when used concurrently. In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010; Levine 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some products may contain phenylalanine, which can be harmful to patients with phenylketonuria (PKU). Before prescribing, consider the combined daily amount of phenylalanine from all sources.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop lansoprazole treatment at least 14 days before CgA test; if CgA level is high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should contact healthcare provider if they have liver disease, heartburn for &gt;3 months, heartburn with dizziness, lightheadedness, or sweating, MI symptoms, frequent chest pain, frequent wheezing (especially with heartburn), unexplained weight loss, nausea/vomiting, stomach pain, or are taking antifungals, atazanavir, digoxin, tacrolimus, theophylline, or warfarin. Patients should stop use and consult a healthcare provider if heartburn continues or worsens, or if they need to take for &gt;14 days or more often than every 4 months. Patients should be informed that it may take 1 to 4 days for full effect to be seen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186800\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186724\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12543&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Lansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Lansoprazole may enhance the dermatologic adverse effect of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186754\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186726\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186741\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. An increased risk of hypospadias was reported following maternal use of proton pump inhibitors (PPIs) during pregnancy (Anderka 2012), but this was based on a small number of exposures and the same association was not found in another study (Erichsen 2012). Most available studies have not shown an increased risk of major birth defects following maternal use of PPIs during pregnancy (Diav-Citrin 2005; Matok 2012; Pasternak 2010). When treating GERD in pregnancy, PPIs may be used when clinically indicated (Katz 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059659\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with Zollinger-Ellison syndrome should be monitored for gastric acid output, which should be maintained at 10 mEq/hour or less during the last hour before the next lansoprazole dose; lab monitoring should include CBC, liver function, renal function, and serum gastrin levels</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186718\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186737\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Gastric acid suppression: Oral: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Gastric acid suppression: Oral: &gt;1 day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Children: 0.61 to 0.9 L/kg; Adults: 15.7 &plusmn; 1.9 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2C19 and 3A4 to inactive metabolites, and in parietal cells to two active metabolites that are not present in systemic circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &gt;80%; decreased 50% to 70% if given 30 minutes after food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children: 1.2 to 1.5 hours; Adults: 1.5 &plusmn; 1 hour; Elderly: 1.9 to 2.9 hours; Hepatic impairment: 4 to 7.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (67%); urine (33%; 14% to 25% as metabolites and &lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 0.57 to 0.71 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 11.1 &plusmn; 3.8 L/hour; Hepatic impairment: 3.2 to 7.2 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186736\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A lansoprazole oral suspension (3 mg/mL) is commercially available as a compounding kit (First-Lansoprazole).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>3 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 3 mg/mL oral solution (Simplified Lansoprazole Solution [SLS]) may be made with capsules and sodium bicarbonate. Empty the contents of ten lansoprazole 30 mg capsules into a beaker. Add 100 mL sodium bicarbonate 8.4% and gently stir until dissolved (about 15 minutes). Transfer solution to an amber-colored syringe or bottle. A prior study showed that SLS was stable for 8 hours at room temperature or for 14 days refrigerated (DiGiancinto 2000). However, a more recent study, demonstrated SLS to be stable for 48 hours at room temperature in oral syringes and for only 7 days when refrigerated (Morrison 2013).</p>\n    <div class=\"reference\">DiGiancinto JL, Olsen KM, Bergman KL, et al, &ldquo;Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(5):600-605.<span class=\"pubmed-id\">10852086</span></div>\r\n\n    <div class=\"reference\">Morrison JT, Lugo RA, Thigpen JC, et al, &ldquo;Stability of Extemporaneously Prepared Lansoprazole Suspension at Two Temperatures,&rdquo; <i>J Pediatr Pharmacol Ther</i>, 2013, 18(2):122-127.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186740\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Lansoprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $176.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (90): $529.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Prevacid 24HR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (14): $11.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Prevacid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $498.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,660.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (First-Lansoprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/mL (150 mL): $87.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Lansoprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $15.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $15.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Prevacid SoluTab Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $1,660.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,660.38</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186743\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agopton (AT, CH, DE);</li>\n      <li>Betalans (ID);</li>\n      <li>Chexid (ET);</li>\n      <li>Dakar (LU);</li>\n      <li>Dapuaa (KR);</li>\n      <li>Daxar (BE);</li>\n      <li>Digest (ID);</li>\n      <li>Dispepci (PT);</li>\n      <li>Emlansa (HK);</li>\n      <li>Estomil (ES);</li>\n      <li>Gastevin (VN);</li>\n      <li>Gastriben (PT);</li>\n      <li>Gastrovex (MY);</li>\n      <li>Hiza (PH);</li>\n      <li>Imidex (MX);</li>\n      <li>Inhipraz (ID);</li>\n      <li>Julphasole (MY);</li>\n      <li>Krovane (MT);</li>\n      <li>Lacopen (CO);</li>\n      <li>Lagas (ID);</li>\n      <li>Lancerol (UA);</li>\n      <li>Lancid (KR);</li>\n      <li>Lanfast (AE, BH, KW, QA, SA);</li>\n      <li>Langaton (KR);</li>\n      <li>Lanodizol (MX);</li>\n      <li>Lanpraz (CO);</li>\n      <li>Lanpro (MY);</li>\n      <li>Lanprol (AE, BH, CY, EG, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Lanproton (CO);</li>\n      <li>Lans OD (PH);</li>\n      <li>Lans-OD (LK);</li>\n      <li>Lansal (FI);</li>\n      <li>Lansale (DK);</li>\n      <li>Lanso (GR, IL, MY);</li>\n      <li>Lansodin (BD);</li>\n      <li>Lansol-30 (HK);</li>\n      <li>Lansomid (QA);</li>\n      <li>Lansone (HU);</li>\n      <li>Lansopep (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lansopram (DK);</li>\n      <li>Lansor (TR);</li>\n      <li>Lansozole (KR);</li>\n      <li>Lanspro-30 (PH);</li>\n      <li>Lanster (KR);</li>\n      <li>Lanston (KR);</li>\n      <li>Lanton (IL);</li>\n      <li>Lanvell (PH);</li>\n      <li>Lanxid-OD (PH);</li>\n      <li>Lanximed (CO);</li>\n      <li>Lanz (BD);</li>\n      <li>Lanzap (RO, RU);</li>\n      <li>Lanzo (DK, IS, SE);</li>\n      <li>Lanzo Melt (NO);</li>\n      <li>Lanzohess (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lanzol (ES, IE);</li>\n      <li>Lanzol-30 (IN);</li>\n      <li>Lanzole (LK);</li>\n      <li>Lanzopra (BD);</li>\n      <li>Lanzopral (AR, PE, PY, UY, VE);</li>\n      <li>Lanzopran (AU);</li>\n      <li>Lanzoptol (UA);</li>\n      <li>Lanzor (AE, BH, DE, EG, FR, JO, KW, LB, QA, SA);</li>\n      <li>Lanzostad (LT, LV);</li>\n      <li>Lanzul (CZ, EE, HR, LT, LV, PL, RO, SI, SK);</li>\n      <li>Lapraz (ID);</li>\n      <li>Laproton (ID);</li>\n      <li>Lasgan (ID);</li>\n      <li>Lasoprol (ET, MT, SG);</li>\n      <li>Laz (ID);</li>\n      <li>Lazo (BD);</li>\n      <li>Lazol (HR);</li>\n      <li>Loprezol (ID);</li>\n      <li>Monolitum (ES);</li>\n      <li>Normitsyd (UA);</li>\n      <li>Ogast (FR);</li>\n      <li>Ogastro (BB, BM, BS, BZ, CO, CR, DO, EC, FR, GT, GY, HN, JM, MX, NI, PA, PE, PR, SR, SV, TT);</li>\n      <li>Olan (MX);</li>\n      <li>Opiren (ES);</li>\n      <li>Palatrin (MX);</li>\n      <li>Prazex (VN);</li>\n      <li>Prevacid (CN, MY, PH, PK, SG, TH, UA);</li>\n      <li>Prevacid FDT/IV (TH);</li>\n      <li>Prezal (NL);</li>\n      <li>Prilosan (MX);</li>\n      <li>Prolanzo (PH);</li>\n      <li>Prosogan fd (ID);</li>\n      <li>Protonexa (BG);</li>\n      <li>Pysolan (ID);</li>\n      <li>Quitulcer (TW);</li>\n      <li>Razolager (IE);</li>\n      <li>Safemar (MX);</li>\n      <li>Solox (NZ);</li>\n      <li>Sopralan-30 (ID);</li>\n      <li>Sopranix (SE);</li>\n      <li>Soprazol (LK);</li>\n      <li>Sorifran (MX);</li>\n      <li>Takepron (AE, BF, BH, BJ, CI, CN, ET, GH, GM, GN, JO, JP, KE, KW, LB, LR, MA, ML, MR, MU, MW, NE, NG, QA, SA, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Takepron OD (HK);</li>\n      <li>Taquidine (TW);</li>\n      <li>Uldapril (MX);</li>\n      <li>Ulpax (MX);</li>\n      <li>Versacid (PH);</li>\n      <li>Xizhixin (CN);</li>\n      <li>Zolcer (ID);</li>\n      <li>Zomel (IE);</li>\n      <li>Zopral (AU);</li>\n      <li>Zopraz (PE);</li>\n      <li>Zoton (AU, GB, IE, IL, IT);</li>\n      <li>Zoton Fastab (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &quot;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&quot; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderka M, Mitchell AA, Louik C, et al, &quot;Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC, and Practice Parameters Committee of the American College of Gastroenterology, &ldquo;American College of Gastroenterology, Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007, 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chun AH, Eason CJ, Shi HH, et al, &quot;Lansoprazole: An Alternative Method of Administration of a Capsule Dosage Formulation,&quot; <i>Clin Ther</i>, 1995, 17(3):441-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/7585848/pubmed\" target=\"_blank\" id=\"7585848\">7585848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O, Arnon J, Shechtman S, et al, &quot;The Safety of Proton Pump Inhibitors in Pregnancy: A Multicentre Prospective Controlled Study,&quot; <i>Aliment Pharmacol Ther</i>, 2005, 21(3):269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/15691301/pubmed\" target=\"_blank\" id=\"15691301\">15691301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erichsen R, Mikkelsen E, Pedersen L, et al, &quot;Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring,&quot; <i>Am J Ther</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/22314213/pubmed\" target=\"_blank\" id=\"22314213\">22314213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frelinger AL 3rd, Lee RD, Mulford DJ, et al, &quot;A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,&quot; <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/22464259/pubmed\" target=\"_blank\" id=\"22464259\">22464259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons TE and Gold BD, &quot;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&quot; <i>Paediatr Drugs</i>, 2003, 5(1):25-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/12513104/pubmed\" target=\"_blank\" id=\"12513104\">12513104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khoshoo V and Dhume P, &quot;Clinical Response to 2 Dosing Regimens of Lansoprazole in Infants With Gastroesophageal Reflux,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2008, 46(3):352-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/18376260/pubmed\" target=\"_blank\" id=\"18376260\">18376260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA, and the Section on Gastroenterology, Hepatology, and Nutrition,&quot; Gastroesophageal Reflux: Management Guidance for the Pediatrician,&quot; <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/23629618/pubmed\" target=\"_blank\" id=\"23629618\">23629618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li XQ, Andersson TB, Ahlstr&ouml;m M, et al, &quot;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&quot; <i>Drug Metab Dispos</i>, 2004, 32(8):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/15258107/pubmed\" target=\"_blank\" id=\"15258107\">15258107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Levy A, Wiznitzer A, et al, &quot;The Safety of Fetal Exposure to Proton-Pump Inhibitors During Pregnancy,&quot; <i>Dig Dis Sci</i>, 2012, 57(3):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/22038541/pubmed\" target=\"_blank\" id=\"22038541\">22038541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oderda G, Chiorboli E, Haitink AR, et al, &quot;Inhibition of Gastric Acidity in Children by Lansoprazole Granules,&quot; <i>Gastroent</i>, 1998, 114(4pt2):A295.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ogilvie BW, Yerino P, Kazmi F, et al, &quot;The Proton Pump Inhibitor, Omeprazole, But Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&quot; <i>Drug Metab Dispos</i>, 2011, 39(11):2020-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/21795468/pubmed\" target=\"_blank\" id=\"21795468\">21795468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orenstein SR, Hassall E, Furmaga-Jablonska W, et al, &quot;Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Assessing the Efficacy and Safety of Proton Pump Inhibitor Lansoprazole in Infants With Symptoms of Gastroesophageal Reflux Disease,&quot; <i>J Pediatr</i>, 2009, 154(4):514-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/19054529/pubmed\" target=\"_blank\" id=\"19054529\">19054529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott LJ, &quot;Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children,&quot; <i>Paediatr Drugs</i>, 2003, 5(1):57-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/12513106/pubmed\" target=\"_blank\" id=\"12513106\">12513106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Springer M, Atkinson S, North J, et al, &quot;Safety and Pharmacodynamics of Lansoprazole in Patients With Gastroesophageal Reflux Disease Aged &lt;1 Year,&quot; <i>Paediatr Drugs</i>, 2008, 10(4):255-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/18590344/pubmed\" target=\"_blank\" id=\"18590344\">18590344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tham SY, Rogers IM, Samuel KF, Singh A, Ong KK. Does oral lansoprazole really reduce gastric acidity in VLBW premature neonates? <i>Med J Malaysia</i>. 2012;67(3):284-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/23082418/pubmed\" target=\"_blank\" id=\"23082418\">23082418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tran A, et al, &quot;Pharmacokinetics/Pharmacodynamics Study of Oral Lansoprazole in Children,&quot; <i>Fundam Clin Pharmacol</i>, 1996, 10:A221.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang W, Kukulka M, Witt G, et al, &quot;Age-Dependent Pharmacokinetics of Lansoprazole in Neonates and Infants,&quot; <i>Paediatr Drugs</i>, 2008, 10(4):265-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lansoprazole-pediatric-drug-information/abstract-text/18590345/pubmed\" target=\"_blank\" id=\"18590345\">18590345</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12543 Version 225.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836891\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186757\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F186758\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059660\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12860309\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059653\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186730\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F186715\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45040050\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15241705\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059664\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F186752\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059663\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F186815\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186813\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186738\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186719\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F186800\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186724\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F186754\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F186726\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186741\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059659\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186718\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F186737\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F186736\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186740\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F186743\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12543|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lansoprazole-drug-information\" class=\"drug drug_general\">Lansoprazole: Drug information</a></li><li><a href=\"topic.htm?path=lansoprazole-patient-drug-information\" class=\"drug drug_patient\">Lansoprazole: Patient drug information</a></li></ul></div></div>","javascript":null}